Truist lowered the firm’s price target on Viridian Therapeutics (VRDN) to $33 from $36 and keeps a Buy rating on the shares. The firm is adjusting its model with refreshed views on volume and pricing ahead of a potential Veli’ launch in active and chronic TED, though it remains positive on the stock given the company’s clear catalyst path ahead, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRDN:
- Viridian: Dual TED Franchise Catalysts Support Favorable Risk‑Reward and Buy Rating
- Viridian Therapeutics price target lowered to $24 from $32 at Evercore ISI
- Viridian Therapeutics price target lowered to $36 from $40 at Truist
- Viridian Therapeutics price target lowered to $31 from $37 at Wedbush
- 3 Best Trending Stocks, According to Analysts – 4/7/2026